Illumina, Inc.: Form 10-Q for the period ended Oct 1, 2023
Filed with the SEC on Nov 13, 2023 and accepted by EDGAR at Nov 9, 2023, 18:30 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-10-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-03 to 2023-10-01 | $1.12bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-01-02 to 2023-10-01 | $3.38bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-07-03 to 2023-10-01 | $435.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2023-01-02 to 2023-10-01 | $1.31bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-07-03 to 2023-10-01 | $684.0m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-01-02 to 2023-10-01 | $2.07bn | us-gaap:GrossProfit |
| Research and development | 3 months2023-07-03 to 2023-10-01 | $315.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-02 to 2023-10-01 | $1.01bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-07-03 to 2023-10-01 | $303.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-01-02 to 2023-10-01 | $1.13bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-07-03 to 2023-10-01 | −$754.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-02 to 2023-10-01 | −$905.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-03 to 2023-10-01 | $19.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-02 to 2023-10-01 | $59.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-03 to 2023-10-01 | −$28.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-02 to 2023-10-01 | $36.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-03 to 2023-10-01 | −$754.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-02 to 2023-10-01 | −$986.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-03 to 2023-10-01 | −$4.77 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-02 to 2023-10-01 | −$6.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-03 to 2023-10-01 | −$4.77 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-02 to 2023-10-01 | −$6.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-03 to 2023-10-01 | 158,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-02 to 2023-10-01 | 158,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-02 to 2023-10-01 | $254.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-02 to 2023-10-01 | $144.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2023-10-01 | $2.51bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-10-01 | $10.12bn | us-gaap:Assets |
| Current liabilities | At period end2023-10-01 | $1.48bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2023-10-01 | $5.90bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001110803-23-000086. Last ingested by Listed: Nov 14, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.